Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1974 1
1976 1
1979 5
1981 2
1982 1
1983 3
1984 5
1985 4
1986 6
1987 5
1988 7
1989 5
1990 5
1991 4
1992 1
1993 6
1994 3
1995 4
1996 3
1997 6
1998 4
1999 7
2000 7
2001 6
2002 6
2003 1
2004 3
2005 4
2006 6
2007 5
2008 7
2009 4
2010 8
2011 13
2012 5
2013 13
2014 12
2015 6
2016 14
2017 11
2018 11
2019 17
2020 15
2021 17
2022 11
2023 20
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy in myopia control.
Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Brennan NA, et al. Prog Retin Eye Res. 2021 Jul;83:100923. doi: 10.1016/j.preteyeres.2020.100923. Epub 2020 Nov 27. Prog Retin Eye Res. 2021. PMID: 33253901 Free article. Review.
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, Stebegg M, Brennan N, Gilbert S, O'Malley JT, Porter-Brown B. Weidinger S, et al. Among authors: brennan n. Br J Dermatol. 2023 Oct 25;189(5):531-539. doi: 10.1093/bjd/ljad240. Br J Dermatol. 2023. PMID: 37463508 Free article. Clinical Trial.
OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.
Saghari M, Gal P, Gilbert S, Yateman M, Porter-Brown B, Brennan N, Quaratino S, Wilson R, Grievink HW, Klaassen ES, Bergmann KR, Burggraaf J, van Doorn MBA, Powell J, Moerland M, Rissmann R. Saghari M, et al. Among authors: brennan n. Clin Pharmacol Ther. 2022 May;111(5):1121-1132. doi: 10.1002/cpt.2539. Epub 2022 Mar 1. Clin Pharmacol Ther. 2022. PMID: 35092305 Free PMC article. Clinical Trial.
Lid wiper epitheliopathy.
Efron N, Brennan NA, Morgan PB, Wilson T. Efron N, et al. Among authors: brennan na. Prog Retin Eye Res. 2016 Jul;53:140-174. doi: 10.1016/j.preteyeres.2016.04.004. Epub 2016 Apr 14. Prog Retin Eye Res. 2016. PMID: 27094372 Review.
Correspondence.
Brennan N, Chan WO, Reekie I, Ezra E, Barton K, Viswanathan A, Muqit MMK. Brennan N, et al. Retina. 2018 Oct;38(10):e86-e87. doi: 10.1097/IAE.0000000000002330. Retina. 2018. PMID: 30247369 No abstract available.
Myopia control: Seeing beyond efficacy.
Bullimore MA, Jong M, Brennan NA. Bullimore MA, et al. Among authors: brennan na. Optom Vis Sci. 2024 Mar 1;101(3):134-142. doi: 10.1097/OPX.0000000000002119. Optom Vis Sci. 2024. PMID: 38546754 Review.
Patient Preparation and Paradigm Design in fMRI.
Gene M, Brennan NP, Holodny AI. Gene M, et al. Among authors: brennan np. Neuroimaging Clin N Am. 2021 Feb;31(1):11-21. doi: 10.1016/j.nic.2020.09.007. Epub 2020 Oct 29. Neuroimaging Clin N Am. 2021. PMID: 33220824 Review.
The future of clinical trials of myopia control.
Bullimore MA, Brennan NA, Flitcroft DI. Bullimore MA, et al. Among authors: brennan na. Ophthalmic Physiol Opt. 2023 May;43(3):525-533. doi: 10.1111/opo.13120. Epub 2023 Mar 10. Ophthalmic Physiol Opt. 2023. PMID: 36897281
288 results